Related Experiment Videos
Antiplatelet therapy in the treatment of cerebrovascular disease
1Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City 73190.
Insights
Aspirin and ticlopidine are effective antiplatelet drugs for preventing vascular events. Ticlopidine shows promise in stroke prevention for both men and women, while aspirin reduces myocardial infarction risk in high-risk men.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Platelet-antiaggregating drugs are crucial for preventing vascular events.
- Aspirin and ticlopidine are leading agents in this therapeutic class.
- Previous research established aspirin's efficacy in specific high-risk male populations.
Purpose of the Study:
- To evaluate the effectiveness of aspirin and ticlopidine in preventing stroke and other vascular events.
- To compare the efficacy of these agents across different patient demographics and risk profiles.
Main Methods:
- Review of numerous clinical trials and large, multicenter studies.
- Analysis of data from primary prevention trials and studies on patients with existing thromboembolic events.
Main Results:
- Aspirin effectively reduces myocardial infarction, transient ischemic attacks, stroke, and vascular death in high-risk men.
- Aspirin also reduces myocardial infarction risk in healthy men over 50 but not stroke risk.
- Ticlopidine demonstrated efficacy in reducing fatal and nonfatal strokes in both men and women.
- Ticlopidine may be beneficial in preventing recurrent strokes post-thromboembolic event.
Conclusions:
- Both aspirin and ticlopidine are valuable antiplatelet agents for vascular event prevention.
- Ticlopidine offers significant benefits for stroke prevention in a broader population than previously established for aspirin.
- Further research may clarify ticlopidine's role in secondary stroke prevention.
Abstract:
Aspirin and the new agent ticlopidine have been the most thoroughly evaluated of the platelet-antiaggregating drugs used for the prevention of stroke and other vascular events. Numerous trials have shown aspirin to be effective in reducing the risk of myocardial infarction (MI), recurrent transient ischemic attacks, stroke, and vascular death in men at high risk for these events. Primary prevention trials have shown that aspirin reduces the risk of MI in healthy men over 50 years of age but does not reduce the risk of stroke. Two large, multicenter trials have shown that ticlopidine is effective in reducing the risk of fatal and nonfatal stroke in both men and women. Ticlopidine may also be effective in reducing the risk of recurrent stroke in patients who have had a completed thromboembolic stroke.